Colorectal Cancer Study
Study Name:
A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination with Pembrolizumab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors
Eligibility:
Patients with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC) who had received at least 2 and no more than 3 prior systemic treatments, including 5-FU/capecitabine, oxaliplatin, irinotecan (regardless of combination in 1 or 2 lines of therapy), with or without the association with monoclonal antibodies (e.g. bevacizumab or cetuximab). And free of liver metastasis, no prior immunotherapy.
Treatment 1:
ADG126 10mg/kg Q3W or Q6W plus Pembrolizumab 200mg Q3W
Treatment 2:
ADG126 20mg/kg loading dose arm plus Pembrolizumab 200mg Q3W
Personal Data Disclosure Disclaimer: We may collect, use, and disclose your personal data in accordance with the Personal Data (Privacy) Ordinance. Your information will be handled with care and only used for the purposes specified at the time of collection.